Genentech reported that data showing new personalized approaches for skin and lung cancer patients, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7.
Roche and Genentech’s investigational and approved cancer medicines will be featured in approximately 300 abstracts across more than 30 cancer types.
“Our goal is to develop cancer medicines that improve care in a way that is meaningful to patients and their doctors,” said Hal Barron, MD, chief medical officer and head of global product development.
Data from a Phase III study (BRIM3) testing Vemurafenib (RG7204/PLX4032) in people with previously untreated metastatic melanoma with a mutated BRAF gene will be presented for the first time, as will an Updated Phase II data (BRIM2).
Data from EURTAC, the first Phase III study of Tarceva compared with chemotherapy in a Western population of people who had not previously been treated for a genetically distinct form of advanced lung cancer will be presented, as will MetMAb, a randomized Phase II data comparing MetMAb plus Tarceva to placebo plus Tarceva in people with advanced lung cancer with high or low levels of the Met receptor (Met diagnostic-positive or -negative).
Avastin, a Phase III data (OCEANS) in women with ovarian cancer that has progressed following initial treatment with platinum-based chemotherapy will be presented for the first time. New analyses from the Phase III ICON7 study in women with newly diagnosed ovarian cancer and with poor prognosis will also be presented.
Release Date: May 17, 2011
Filed Under: Drug Discovery